Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Goodwill and Other Intangible Assets

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]


.	Goodwill and Other Intangible Assets

Goodwill recorded as of December 31, 2014 of $15.5 million is attributable to the 2014 acquisition of RedPath. Goodwill recorded as of December 31, 2013 was attributable to the 2010 acquisition of Group DCA and has been reclassified as held-for-sale. See Note19, Discontinued Operations for further information.

Goodwill

In connection the Company's decision to dispose of Group DCA, the Company reclassed the $2.5 million goodwill balance to assets held-for-sale within Other non-current assets in the consolidated balance sheet as of December 31, 2014 and impaired $1.2 million of the goodwill associated with the 2010 acquisition of Group DCA as the fair value of the Group DCA reporting unit was below its carrying value including goodwill, leaving a balance of $1.3 million. A rollforward of the carrying value of goodwill from continuing operations from January 1, 2014 to December 31, 2014 is as follows:



	2014
	January 1,		Additions		Adjustments		Impairments		December 31,
RedPath	$	—	$	15,545	$	—	$	—	$	15,545

Other Intangible Assets

The net carrying value of the identifiable intangible assets as of December 31, 2014 is as follows:



		As of December 31, 2014
	Life	Carrying		Accumulated
	(Years)	Amount		Amortization		Net
Diagnostic assets:
Asuragen acquisition:
Thyroid	9	$	8,519	$	—	$	8,519
Pancreas	7	2,882		154		2,728
Biobank	4	1,575		147		1,428
RedPath acquisition:
Pancreas test	7	16,141		385		15,756
Barrett's test	9	18,351		—		18,351
Total		$	47,468	$	686	$	46,782
Diagnostic lab:
CLIA Lab	2.3	$	609	$	87	$	522

Amortization expense was $0.8 million for the year ended December 31, 2014. There was no amortization expense for the year ended December 31, 2013. Amortization of the thyroid diagnostic asset will begin upon launch of the product. Estimated amortization expense for the next five years is as follows:



2015		2016		2017		2018		2019
$	5,102	$	6,358	$	6,097	$	5,949	$	5,703

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details